Pelubiprofen is a new member of the class of non-steroidal anti-inflammatory drugs for the treatment of back pain and pain in rheumatic musculoskeletal disorders

On December 18, 2024, a meeting of the Expert Council was held to discuss approaches to the treatment of non-specific back pain and pain in rheumatic musculoskeletal disorders. It was noted that non-steroidal anti-inflammatory drugs (NSAIDs) remain the mainstay of therapy for inflammation-related pain and that optimal therapy should provide a balance between high efficacy and good tolerability in each patient. A new NSAID, pelubiprofen (Pelubio®), has been registered in the Russian Federation. According to research data, its efficacy is comparable to that of non-selective and selective NSAIDs and at the same time the drug has a high safety profile. The resolution of the Expert Council states that this medicine can be prescribed within the framework of Russian clinical practice, considering the registered indications for pelubiprofen and the clinical guidelines adopted in Russia for the treatment of acute and chronic non-specific back pain, radiculopathy, osteoarthritis (including gonarthrosis and coxarthrosis) and rheumatoid arthritis.

1. Clinical recommendations of the Interregional Public Organization "Society for the Study of Pain" – Musculoskeletal (nonspecific) pain in the lower back Approved by the Ministry of Health of the Russian Federation, M54.5 Year of approval (frequency of revision): 2023. Adults.

2. Draft clinical guidelines for the diagnosis and treatment of primary osteoarthritis, Russian Scientific Medical Society of Internists, Association of Rheumatologists of Russia, 2022.

3. Nasonov EL, Karateev DE, Balabanova RM. Rheumatoid arthritis. In: Nasonov EL, Nasonova VA, editors. Rheumatology. National guidelines. Moscow: GEOTAR-Media; 2008. P. 290-331.

4. World Health Organization. Musculoskeletal health. 14 July 2022. https://www.who.int/news-room/fact-sheets/detail/musculoskeletal-conditions

5. Liu S, Wang B, Fan S, et al. Global burden of musculoskeletal disorders and attributable factors in 204 countries and territories: a secondary analysis of the Global Burden of Disease 2019 study. BMJ Open. 2022 Jun 29;12(6): e062183. doi: 10.1136/bmjopen-2022-062183.

6. https://rosstat.gov.ru/storage/mediabank/Zdravoohran-2023.pdf

7. Nasonov EL, Yakhno NN, Karateev AE, et al. General principles of musculoskeletal pain treatment: interdisciplinary consensus. Nauchno-prakticheskaya revmatologiya. 2016;54(3):247-265. (In Russ.).

8. Karateev AE. Chronic musculoskeletal pain: pathogenesis, clinical features, treatment options. Klinicheskaya meditsina. 2022; (11-12):527-534. (In Russ.).

9. Karateev AE, Karateev DE, Davydov OS. Pain and inflammation. Part 1. Pathogenetic aspects. Nauchno-prakticheskaya revmatologiya. 2016;54(6):693-704. (In Russ.).

10. Salucci S, Falcieri E, Battistelli M. Chondrocyte death involvement in osteoarthritis. Cell Tissue Res. 2022 Aug;389(2):159-170. doi: 10.1007/s00441-022-03639-4. Epub 2022 May 26.

11. Yang J, Hu S, Bian Y, et al. Targeting Cell Death: Pyroptosis, Ferroptosis, Apoptosis and Necroptosis in Osteoarthritis. Front Cell Dev Biol. 2022 Jan 18:9:789948. doi: 10.3389/fcell. 2021.789948. eCollection 2021.

12. Khir NAM, Noh ASM, Long I, et al. Inflammatory-associated apoptotic markers: are they the culprit to rheumatoid arthritis pain? Mol Biol Rep. 2022 Oct;49(10):10077- 10090. doi: 10.1007/s11033-022-07591-y. Epub 2022 Jun 14.

13. Arendt-Nielsen L, Morlion B, Perrot S, et al. Assessment and manifestation of central sensitisation across different chronic pain conditions. Eur. J. Pain. 2018;22(2):216–41. doi: 10.1002/ejp.1140

14. Karateev AE, Nasonov EL, Ivashkin VT, et al. Rational use of nonsteroidal anti-inflammatory drugs. Clinical recommendations. Nauchno-prakticheskaya revmatologiya. 2018; 56:1-29. (In Russ.).

15. Gianola S, Bargeri S, Del Castillo G. Effectiveness of treatments for acute and subacute mechanical non-specific low back pain: a systematic review with network meta-analysis. Br J Sports Med. 2022 Jan;56(1):41-50. doi: 10.1136/bjsports-2020-103596. Epub 2021 Apr 13

16. Van der Gaag WH, Roelofs PD, Enthoven WT, et al. Non-steroidal anti-inflammatory drugs for acute low back pain. Cochrane Database Syst Rev. 2020 Apr 16;4(4): CD013581. doi: 10.1002/14651858.CD013581.

17. Cashin AG, Wand BM, O'Connell NE, et al. Pharmacological treatments for low back pain in adults: an overview of Cochrane Reviews. Cochrane Database Syst Rev. 2023 Apr 4;4(4):CD013815. doi: 10.1002/14651858. CD013815.pub2.

18. Osani MC, Vaysbrot EE, Zhou M, et al. Duration of symptom relief and early trajectory of adverse events for oral nonsteroidal antiinflammatory drugs in knee osteoarthritis: A systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2020 May;72(5): 641-651. doi: 10.1002/acr.23884. Epub 2020 Apr 14.

19. Severin ES, editor. Biochemistry: textbook for high schools. Moscow: GEOTAR-Media; 2003.

20. Sostres C, Gargallo C, Lanas A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther. 2013;15 Suppl 3(Suppl 3) :S3. doi: 10.1186/ar4175. Epub 2013 Jul 24.

21. Laine L. Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs – nice or necessary? Rev Gastroenterol Disord. 2004:4 Suppl 4:S33-41.

22. Fries J, Kristen N, Bennet M, et al. The rise and decline of nonsteroidal anti-inflammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis Rheum. 2004 Aug;50(8):2433-40. doi: 10.1002/art.20440.

23. Cheng Y, Austin S, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science. 2002 Apr 19; 296(5567):539-41. doi: 10.1126/science.1068711.

24. Grosser T, Fries S, FitzGerald G. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenes an opportunity. J Clin Invest. 2006 Jan;116(1): 4-15. doi: 10.1172/JCI27291.

25. Schaeverbeke T, Heloire F, Deray G. How to watch over a patient treated with a NSAID in relation to the cardiovascular and renal risk? Presse Med. 2006 Sep;35 Suppl 1: 41-6. doi: 10.1016/S0755-4982(06)74939-9.

26. Clinical recommendations of the Association of Rheumatologists of Russia, NGO "Russian Rheumatological Association "Nadezhda" – Rheumatoid arthritis: 2021. Adults.

27. Clinical recommendations for Coxarthrosis Have been Approved by the Ministry of Health of the Russian Federation, M16 Year of approval (frequency of revision): 2024. Adults.

28. Gonartrosis Clinical Recommendations Are Approved by the Ministry of Health of the Russian Federation, M17 Year of approval (frequency of revision): 2024. Adults.

29. Registration certificate of the medicinal product Pelubio LP-№ (005121)-(RG-RU) https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=c78c87d9-238b-45d8-b564-52ab47b02c6e

30. Instructions for medical use of the medicinal product Pelubio®, LP-№ (005121)-(RG-RU)-090424.

31. Shin JS, Baek SR, Sohn SI, et al. Anti-inflammatory effect of pelubiprofen, 2-[4-(oxocyclohexylidenemethyl)-phenyl] propionic acid, mediated by dual suppression of COX activity and LPS-induced inflammatory gene expression via NF-κB inactivation. J Cell Biochem. 2011 Dec;112(12):3594-603. doi: 10.1002/jcb.23290.

32. Chou R, McDonagh MS, Nakamoto E, et al. Analgesics for Osteoarthritis: An Update of the 2006 Comparative Effectiveness Review [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 Oct. (Comparative Effectiveness Reviews, № 38.) Appendix B, Cyclooxygenase Selectivity of NSAIDs. Available from: https://www.ncbi.nlm.nih.gov/books/NBK65642/

33. Hunter TS, Robison C, Gerbino PP. Emerging evidence in NSAID pharmacology: important considerations for product selection. Am J Manag Care. 2015 Apr;21(7 Suppl): S139-47. PMID: 26168321.

34. Kato M, Nishida S, Kitasato H, Sakata N, Kawai S. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes. J Pharm Pharmacol. 2001 Dec;53(12):1679-85. doi: 10.1211/0022357011778070

35. Shin BJ, Kim TK, Baik JS, Shim DM. Comparison The Safety and The Efficacy between the Group of using Pelubiprofen Tab. and the Group of using Aceclofenac Tab. on Back Pain Patients – Multi Institution, Double Blind, Random Sample. J Korean Soc Spine Surg. 2012 Jun;19(2):38-46. doi: 10.4184/jkss.2012.19.2.38

36. Shin JY, Chang MJ, Kim MK, et al. Efficacy and safety of short-term use of a pelubiprofen CR and aceclofenac in patients with symptomatic knee osteoarthritis: A doubleblinded, randomized, multicenter, active drug comparative, parallel-group, phase IV, noninferiority clinical trial. PLoS One. 2020 Sep 29;15(9): e0238024. doi: 10.1371/journal.pone.0238024.

37. Permission of the Ministry of Health of the Russian Federation to conduct CI № 353 dated 07/22/2020. https://grls.rosminzdrav.ru/CIPermissionMini.aspx?CIStatementGUID=c9d529a1-63e9-4a10-9b3b-70cd4b29ed81&CIPermGUID=0cddf502-4b64-4bda-8acc-f060ea2fa083

38. Choi IA, Baek HJ, Cho CS, et al. Comparison of the efficacy and safety profiles of a pelubiprofen versus celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, phase III, non-inferiority clinical trial. BMC Musculoskelet Disord. 2014 Nov 18:15:375. doi: 10.1186/1471-2474-15-375.